Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a clinical-stage biomedical company focused on developing and commercializing innovative therapies for cardiovascular and cardiometabolic diseases. The company completed its business combination with Health Assurance Acquisition Corp, a healthcare-focused special purpose acquisition company, and began trading under the OBIO ticker in early 2023. Orchestra BioMed's pipeline includes BackBeat Cardiac Neuromodulation Therapy, developed in partnership with Medtronic, targeting hypertension management in pacemaker-indicated patients. The company filed an 8-K current report with the SEC on September 8, 2026. For complete filing history, deal terms, and up-to-date corporate developments on OBIO and hundreds of other SPAC-originated companies, sign up for full data access at SpacDesk.